Form 4: Climb Bio Director Andrew Levin Reports Acquisition of 40,000 Stock Options

Climb Bio, Inc. Director and 10% owner Andrew Levin reported the acquisition of 40,000 stock options with an exercise price of $1.29, which are held for the benefit of RA Capital Management funds.

Summary

• Andrew David Levin, a Director and 10% owner of Climb Bio, Inc. (CLYM), acquired 40,000 stock options.
• The transaction date for the option grant was June 4, 2025.
• The exercise price for these options is $1.29 per share.
• The options will vest on the earlier of June 4, 2026, or the date immediately prior to the next annual meeting of stockholders, contingent on Mr. Levin's continued service.
• The expiration date for these stock options is June 3, 2035.
• Mr. Levin disclaims beneficial ownership of the stock option and underlying common stock, as he holds them for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account.
• Any net cash or stock received upon exercise is to be turned over to RA Capital Management, L.P. to offset advisory fees owed by the aforementioned funds and account.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of an equity grant to a director, which is generally a positive for aligning interests. The disclaimer of beneficial ownership by the individual director, while explained by the fund arrangement, slightly tempers the direct personal investment signal.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The exercise price of $1.29 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• No direct negatives for the company's financial performance are indicated in this Form 4 filing.

Risks

• The reporting person disclaims beneficial ownership of the stock option and underlying common stock, as they are held for the benefit of RA Capital Management funds, which could imply a lack of direct personal financial stake for the individual director beyond their role as an agent for the funds.

Future Outlook

The vesting schedule of the stock options, tied to continued service through June 4, 2026, or the next annual meeting, indicates an expectation of continued tenure for Director Andrew Levin.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transaction, common in the biotechnology or life sciences industry for directors and executives, often as part of their compensation package or as an investment by associated funds. The involvement of RA Capital Management, a prominent healthcare-focused investment firm, suggests their continued interest and investment in Climb Bio, Inc.

Corporate Governance

Related Party Transactions

• The stock option is held by Andrew Levin for the benefit of RA Capital Management, L.P. funds (RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund II, RA Capital Nexus Fund III, and a separately managed account).
• Mr. Levin is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P. to offset advisory fees owed by these funds. This constitutes a related party arrangement where the director acts on behalf of entities managed by RA Capital, which also holds a 10% ownership stake in Climb Bio.

Stakeholder Impact

• Shareholders: The grant of options to a director can align management interests with shareholder value creation. The 10% ownership by RA Capital Management, through which the director is associated, indicates significant institutional investment.

Next Steps

• The stock options are subject to vesting on the earlier of June 4, 2026, or the date immediately prior to the next annual meeting of stockholders.
• Andrew Levin is obligated to turn over any net cash or stock from the option exercise to RA Capital Management, L.P.

Key Dates

Keywords

Climb Bio, CLYM, Andrew Levin, Stock Option, SEC Form 4, Insider Trading, Beneficial Ownership, RA Capital Management, Director Compensation, Equity Grant